BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China

  Clover Biopharmaceuticals, Ltd. announced that it entered into an exclusive agreement with Adimmune Corporation for Clover to distribute AdimFlu-S in mainland China, where it is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older.

  February 19, 2023

   · 

  6 min read
• Policy

  Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma

  WestVac Biopharma Co., Ltd. has made significant progress on the development of the trivalent recombinant protein COVID-19 vaccine against the latest prevalent subvariants including XBB.1.5 and BA.5, which is one of the first trivalent recombinant protein vaccines targeting XBB.1.5 worldwide.

  February 19, 2023

   · 

  2 min read
• Drug Development

  Detailed Results from Telix’s ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU

  Telix Pharmaceuticals Limited announces detailed positive results from its completed pivotal Phase III ZIRCON trial.

  February 19, 2023

   · 

  10 min read
• Policy

  Astellas Provides Update on Fezolinetant New Drug Application in U.S.

  Astellas Pharma Inc. announced the U.S. Food and Drug Administration notified the company that it is extending the original priority review Prescription Drug User Fee Act goal date for fezolinetant, an investigational agent for the treatment of moderate to severe vasomotor symptoms due to menopause.

  February 19, 2023

   · 

  4 min read
• Business

  Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue

  Daewoong Pharmaceutical announced its 2022 annual report. On a standalone basis, sales increased from the previous year by 10.1% to KRW 1.16 trillion with business profits increased by 11.0% to KRW 106 billion and net profits increased by 123.9% to KRW 80.1 billion, respectively.

  February 19, 2023

   · 

  4 min read
• GC Biopharma Receives WHO Pre-Qualification for BARYCELA

  GC Biopharma, a leading provider of biopharmaceutical products in South Korea, announced that the World Health Organization has granted prequalification for BARYCELA, GC Biopharma’s varicella vaccine.

  February 19, 2023

   · 

  2 min read